sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial

NCT00533039 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Varespladib (A-002)
DRUG: placebo

Sponsor

University Health Network, Toronto

Collaborators

[object Object]